Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 1.00 |
| ▸ | GAPDH | P04406 | 3/20 | 0.46 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | STAT6 | P42226 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22704695 | 0.79 | HIF1A (0.65) | HIF1AGAPDHDOT1LADORA3SMN1; SMN2 | |
| SCHEMBL3297374 | 0.79 | HIF1A (0.65) | HIF1AGAPDHDOT1LADORA3SMN1; SMN2 | |
| Formycin SCHEMBL980049 | 0.76 | HIF1A (0.61) | HIF1AGAPDHDOT1LADORA3SMN1; SMN2 | |
| Formycin SCHEMBL14074914 | 0.76 | HIF1A (0.61) | HIF1AGAPDHDOT1LADORA3SMN1; SMN2 | |
| Formycin SCHEMBL15262901 | 0.76 | HIF1A (0.61) | HIF1AGAPDHDOT1LADORA3SMN1; SMN2 | |
| SCHEMBL3301771 | 0.73 | HIF1A (0.58) | HIF1AGAPDHDOT1LADORA3SMN1; SMN2 | |
| SCHEMBL12261313 | 0.72 | HIF1A (0.57) | HIF1AGAPDHDOT1LADORA3SMN1; SMN2 | |
| Formycin SCHEMBL10149284 | 0.71 | HIF1A (0.55) | HIF1AGAPDHDOT1LADORA3SMN1; SMN2 | |
| Formycin SCHEMBL4196088 | 0.71 | HIF1A (0.55) | HIF1AGAPDHDOT1LADORA3SMN1; SMN2 | |
| SCHEMBL3304855 | 0.70 | PNP (0.58) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473527-B2 | Compounds promoting delivery of genes | THE UAB RESEARCH FOUNDATION (US) | 2009-01-06 | — | — | US | claimed |
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-9504729-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-02-04 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-9186365-B2 | Antiangiogenic small molecules and methods of use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-11-17 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2012-05-24 | — | — | US | disclosed |
| WO-2011014825-A2 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160030508-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | HIF1A 85/4885GAPDH 686/4885DOT1L 3592/4885 |
| US-20120129775-A1 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE | VEGFA, FLT4, KDR | HIF1A 85/4885GAPDH 686/4885DOT1L 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.